Genetic Testing for Ovarian Cancer

Patients with resistant or refractory ovarian cancer experience clinical benefits after receiving botensilimab plus balstilimab in the phase 1 C-800 study.

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

The Carolina Frailty Index Score indicates that patients with ovarian cancer classified as frail are highly more likely to die than patients classified as robust.

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

A post hoc analysis demonstrated that dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival among patients with newly diagnosed, advanced ovarian cancer.

Durvalumab plus tremelimumab in combination with neoadjuvant chemotherapy did not yield any major adverse effects in patients with newly diagnosed advanced ovarian cancer in the phase 2 KGOG3046 trial.